A recent pooled analysis of four key NSCLC trials, including pembrolizumab in both upfront (KEYNOTE 024 and KEYNOTE 042) and second-line (KEYNOTE 001 and KEYNOTE 010) settings, highlights an overall survival benefit regardless of brain metastasis presence or PD-L1 expression levels. The gene discussed is CD274; the disease is non-small cell lung carcinoma.